Sunstone Life Science Ventures

Teitur Trophics is a biotech company established in 2020 and based in Aarhus, Denmark. The company specializes in the development of circular peptides aimed at addressing neurodegenerative diseases. Its research focuses on small peptides that interact with receptors central to neural function. By gaining insights into the biology of these receptors, Teitur Trophics aims to modulate key mechanisms in neural function, which may facilitate the creation of innovative treatments. These treatments are designed to be administered through daily injections, with the potential to prevent the onset of neurodegenerative conditions.

Templafy ApS, established in 2013, specializes in template and document management solutions. Its core product, the Templafy platform, connects and manages an organization's entire document ecosystem. Key features include template and content accessibility, dynamic personalization, document automation, brand and content validation, template governance, and PowerPoint productivity services. Templafy serves a wide range of industries, including banking, consulting, education, insurance, and legal, with a global presence across North America, Europe, Asia, and Australia. The company's innovative platform automates business document creation, ensuring brand compliance, governance, and improved productivity. It supports over 800 enterprise customers worldwide, such as KPMG and IKEA, and has raised $200 million in funding from prominent investors.

Grandhood is a Danish investment management firm established in 2016, headquartered in Copenhagen. The company specializes in retirement planning and pension services, aiming to modernize the traditionally stagnant workplace pension industry through digital innovation. Grandhood offers an online platform that enables employers to provide pensions to their employees, along with voluntary health insurance and other benefits. The platform facilitates digital onboarding and provides advisory services at a competitive cost, ensuring swift customer support. Grandhood continually updates its product to adapt to evolving consumer needs, targeting companies embracing digital solutions for workplace pension management.

Orphazyme develops innovative therapies for treating lysosomal storage diseases, a family of serious genetic disorders. Based in Copenhagen, Denmark, the company collaborates with leading academic institutions worldwide.

Orphazyme develops innovative therapies for treating lysosomal storage diseases, a family of serious genetic disorders. Based in Copenhagen, Denmark, the company collaborates with leading academic institutions worldwide.

Templafy ApS, established in 2013, specializes in template and document management solutions. Its core product, the Templafy platform, connects and manages an organization's entire document ecosystem. Key features include template and content accessibility, dynamic personalization, document automation, brand and content validation, template governance, and PowerPoint productivity services. Templafy serves a wide range of industries, including banking, consulting, education, insurance, and legal, with a global presence across North America, Europe, Asia, and Australia. The company's innovative platform automates business document creation, ensuring brand compliance, governance, and improved productivity. It supports over 800 enterprise customers worldwide, such as KPMG and IKEA, and has raised $200 million in funding from prominent investors.

Orphazyme develops innovative therapies for treating lysosomal storage diseases, a family of serious genetic disorders. Based in Copenhagen, Denmark, the company collaborates with leading academic institutions worldwide.

Issuu, Inc. is a digital publishing and discovery platform founded in 2006, with headquarters in Palo Alto, California, and additional offices in Berlin and Copenhagen. The company offers a comprehensive suite of tools for digital publishing, allowing users to create and share a variety of content, including magazines, newspapers, catalogs, and portfolios. With a focus on enhancing the reader experience, Issuu supports over 17 million publications and serves more than 80 million active readers each month. The platform enables publishers, both large and small, to easily upload and distribute their work while maintaining the visual appeal associated with print media. Moreover, Issuu provides various features, such as custom viewer themes, API integrations, and monetization solutions, which facilitate seamless publication management and audience engagement across devices and social networks.

Templafy ApS, established in 2013, specializes in template and document management solutions. Its core product, the Templafy platform, connects and manages an organization's entire document ecosystem. Key features include template and content accessibility, dynamic personalization, document automation, brand and content validation, template governance, and PowerPoint productivity services. Templafy serves a wide range of industries, including banking, consulting, education, insurance, and legal, with a global presence across North America, Europe, Asia, and Australia. The company's innovative platform automates business document creation, ensuring brand compliance, governance, and improved productivity. It supports over 800 enterprise customers worldwide, such as KPMG and IKEA, and has raised $200 million in funding from prominent investors.

FBC Device ApS, established in 2005 and headquartered in Risskov, Denmark, specializes in manufacturing and marketing spinal fusion implants. The company's flagship product, the Statur implant series, received CE mark approval in 2013, signifying its compliance with European safety and performance standards. This milestone, coupled with ISO 13485 certification for quality management systems, positioned FBC Device to enter both European and Canadian markets. The company's innovative two-piece anterior interbody fusion implant features tantalum spheres as radiologic markers, allowing surgeons to adjust lordosis intraoperatively and potentially enhancing sagittal balance and clinical outcomes for patients undergoing spinal fusion procedures.

Mofibo, founded in Copenhagen in 2013, is one of the pioneering book subscription services globally. The company provides e-books through a proprietary platform that operates on a monthly subscription model, allowing consumers to access a diverse range of titles. Currently active in three countries, Mofibo plans to expand its reach into additional markets within the next year. With a focus on transforming the reading experience, Mofibo employs a data-driven and customer-centric approach to enhance how millions of people interact with books.

Santaris Pharma A/S is a privately held clinical-stage biopharmaceutical company based in Denmark, specializing in the discovery and development of RNA-targeted therapies. Utilizing its proprietary Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine, the company focuses on delivering potent single-stranded LNA-based drug candidates for various disease states. Santaris Pharma's research and development efforts primarily target infectious diseases and cardiometabolic disorders, while also engaging in partnerships with major pharmaceutical companies to address a broader range of therapeutic areas, including cancer, cardiovascular disease, and rare genetic disorders. Founded in 2003, the company holds exclusive worldwide rights for the manufacture and sale of products containing LNA as an active ingredient, supporting its goal of obtaining marketing approval for its innovative therapies.

Nuevolution is a prominent small molecule lead discovery company established in 2001 and headquartered in Copenhagen, Denmark. The firm specializes in developing innovative treatments for human diseases, particularly in oncology and inflammatory conditions. Central to its operations is Chemetics®, a proprietary drug discovery platform that combines wet chemistry with molecular biology, allowing for the rapid synthesis and DNA-tagging of millions of diverse small molecule compounds. This advanced technology enables efficient screening to identify potent drug leads at an unprecedented scale and speed. With a library exceeding 1 billion compounds, Nuevolution collaborates with various pharmaceutical and biotechnology companies, including notable partnerships with leading industry names. Additionally, the company is involved in a joint venture focused on the discovery and development of small molecule drugs targeting epigenetic factors. Nuevolution's capabilities have led to the identification of novel ligands with potential applications in addressing significant unmet medical needs across various therapeutic areas. The company is privately owned by a group of key Scandinavian investors.

Adenium Biotech ApS is a Copenhagen-based biopharmaceutical company founded in 2011, specializing in the development and commercialization of novel antibiotics aimed at treating multi-drug resistant bacterial infections. The company focuses on addressing hospital-acquired infections, particularly complicated urinary tract infections and pneumonia caused by resistant Gram-negative bacteria such as Escherichia coli, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter baumannii. Its lead product, Arenicin, is a 21-amino acid antimicrobial peptide derived from the lugworm, demonstrating strong efficacy against Gram-negative pathogens while maintaining a broad therapeutic window. Adenium Biotech operates as a semi-virtual company, relying on a small team of experts supported by an international scientific advisory board to advance its clinical development programs toward regulatory approval.

Orphazyme develops innovative therapies for treating lysosomal storage diseases, a family of serious genetic disorders. Based in Copenhagen, Denmark, the company collaborates with leading academic institutions worldwide.

Orphazyme develops innovative therapies for treating lysosomal storage diseases, a family of serious genetic disorders. Based in Copenhagen, Denmark, the company collaborates with leading academic institutions worldwide.

Podio, a collaborative work platform now part of Citrix, is designed to enhance how teams manage their daily tasks and workflows. It empowers users to create customized workspaces that can be accessed in real-time by team members, integrating various functionalities such as messaging, task management, reporting, and contact management. By offering a wide range of specialized and flexible work applications, Podio streamlines processes and reduces the need for multiple disjointed tools, all while providing a single, organized environment for users. Trusted by thousands of teams and organizations globally, Podio facilitates efficient work processes and connects various work activities within a cohesive platform. Based in Copenhagen, the company has a diverse team comprising employees from Germany, France, Britain, and Denmark, led by CEO Tommy Ahlers.

Acarix is a medical technology company that develops AI‑based diagnostic solutions for coronary artery disease. Its flagship product, the CADScor system, is CE‑marked and has received FDA DeNovo approval, enabling rapid exclusion of CAD in patients with chest pain and reducing unnecessary invasive procedures. The company originated in 2009 as a spin‑out from Coloplast, with major shareholders Coloplast and Aalborg University, and has secured venture capital from Seed Capital, Sunstone Capital, and Seventure Partners, as well as public funding from the Danish Business Innovation Fund.

Action Pharma A/S is a biotechnology company focused on research and development of innovative drug candidates aimed at treating cardiovascular, inflammatory, and metabolic diseases. Founded in 2000 and based in Holte, Denmark, the company specializes in discovering and developing new treatment concepts, particularly those targeting melanocortin receptors. Its product pipeline includes AP214, a modified peptide analogue for preventing post-surgical kidney injury related to cardiac surgeries, as well as the AP1030 and AP11 series, which are oral anti-diabetic medications designed for patients with type-II diabetes who are overweight or obese. Additionally, Action Pharma is developing AP1189, an oral anti-inflammatory compound for conditions like inflammatory bowel disease and rheumatoid arthritis, and AP405, which targets inflammatory skin diseases such as atopic dermatitis. The company's efforts are geared toward achieving clinical proof of concept for its drug candidates, facilitating partnerships for further development and commercialization.

Biomonitor, founded in 2003 by Professor Klaus Bendtzen and Arsalan Kharazmi as a spinout from the University of Copenhagen, specializes in providing biopharmaceutical development services to pharmaceutical and biotechnology companies. The company's foundation is rooted in Professor Klaus Bendtzen's extensive research on inflammation and immunology at the Copenhagen University Hospital. Biomonitor offers advanced biotechnology tools and methods to assist developers in designing and clinically evaluating their drug candidates, with a particular focus on monitoring biopharmaceuticals to ensure effective treatment outcomes for patients.

Action Pharma A/S is a biotechnology company focused on research and development of innovative drug candidates aimed at treating cardiovascular, inflammatory, and metabolic diseases. Founded in 2000 and based in Holte, Denmark, the company specializes in discovering and developing new treatment concepts, particularly those targeting melanocortin receptors. Its product pipeline includes AP214, a modified peptide analogue for preventing post-surgical kidney injury related to cardiac surgeries, as well as the AP1030 and AP11 series, which are oral anti-diabetic medications designed for patients with type-II diabetes who are overweight or obese. Additionally, Action Pharma is developing AP1189, an oral anti-inflammatory compound for conditions like inflammatory bowel disease and rheumatoid arthritis, and AP405, which targets inflammatory skin diseases such as atopic dermatitis. The company's efforts are geared toward achieving clinical proof of concept for its drug candidates, facilitating partnerships for further development and commercialization.

Santaris Pharma A/S is a privately held clinical-stage biopharmaceutical company based in Denmark, specializing in the discovery and development of RNA-targeted therapies. Utilizing its proprietary Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine, the company focuses on delivering potent single-stranded LNA-based drug candidates for various disease states. Santaris Pharma's research and development efforts primarily target infectious diseases and cardiometabolic disorders, while also engaging in partnerships with major pharmaceutical companies to address a broader range of therapeutic areas, including cancer, cardiovascular disease, and rare genetic disorders. Founded in 2003, the company holds exclusive worldwide rights for the manufacture and sale of products containing LNA as an active ingredient, supporting its goal of obtaining marketing approval for its innovative therapies.

Issuu, Inc. is a digital publishing and discovery platform founded in 2006, with headquarters in Palo Alto, California, and additional offices in Berlin and Copenhagen. The company offers a comprehensive suite of tools for digital publishing, allowing users to create and share a variety of content, including magazines, newspapers, catalogs, and portfolios. With a focus on enhancing the reader experience, Issuu supports over 17 million publications and serves more than 80 million active readers each month. The platform enables publishers, both large and small, to easily upload and distribute their work while maintaining the visual appeal associated with print media. Moreover, Issuu provides various features, such as custom viewer themes, API integrations, and monetization solutions, which facilitate seamless publication management and audience engagement across devices and social networks.